In an IgE-mediated allergic conjunctivitis model, administration of recombinant Gal-1 (rGal-1) resulted in the resolution of clinical signs of conjunctivitis and decreased the production of Th2 cytokines and chemokines [11]. The gene discussed is IGHE; the disease is atopic conjunctivitis.